Top Glycobiology Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the Glycobiology Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading Glycobiology industry players.

Glycobiology Market Competitive Landscape

​ The glycobiology market is characterized by strong competition among the leading companies such as Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, Bruker Corporation, and New England Biolabs. They are all spending a lot of money on research and development to enhance their product portfolios and maintain top position in the market. For instance, Merck KGaA announced investment of over USD 320 million in a new Life Science Research Center in Germany, Darmstadt, to focus on mRNA and antibody production applications, the very essence of glycobiology research. Strategic partnerships and mergers and acquisitions also play important roles in determining market trends. Bruker Corporation's acquisition of IonSense in 2022 was to boost its mass spectrometry capabilities, a major application domain for glycan analysis. Similarly, GlycoNet's collaboration with BridgeBio Pharma in 2021 was to develop drugs for genetic diseases based on glycobiology research.

Government initiatives have a major contribution towards building market development. In America, the National Institutes of Health (NIH) established programs for the advancement of research in glycobiology by funding glycan science liberally. In Europe, institutions like the Deustch Forschungsgemeinschaft in Germany and the European Commission provide funding for glycoscience research, contributing to development in the area.

Top Player’s Company Profiles

  • Thermo Fisher Scientific (US)
  • New England Biolabs (US)
  • Merck KGaA (Germany)
  • Promega Corporation (US)
  • Waters Corporation (US)
  • Takara Bio Inc, (Japan)
  • Bio-Techne (US)
  • Agilent Technologies (US)
  • Sumitomo Bakelite Co. Ltd. (Japan)
  • Bruker Corporation (US)
  • Shimadzu Corporation (Japan)
  • Danaher Corporation (US)
  • AMS Bio (UK)
  • Ludger Ltd (UK)
  • Z Biotech, LLC (US)
  • Chemily Glycoscience (US)
  • CD BioGlyco (US)
  • GlycoDiag (France)
  • Kode Biotech Limited (New Zealand)
  • Glyxera GmBH (Germany)

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

Global Glycobiology Market size was valued at USD 2.3 Billion in 2024 and is poised to grow from USD 2.64 Billion in 2025 to USD 8.02 Billion by 2033, growing at a CAGR of 14.9% during the forecast period (2026–2033).

​ The glycobiology market is characterized by strong competition among the leading companies such as Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, Bruker Corporation, and New England Biolabs. They are all spending a lot of money on research and development to enhance their product portfolios and maintain top position in the market. For instance, Merck KGaA announced investment of over USD 320 million in a new Life Science Research Center in Germany, Darmstadt, to focus on mRNA and antibody production applications, the very essence of glycobiology research. Strategic partnerships and mergers and acquisitions also play important roles in determining market trends. Bruker Corporation's acquisition of IonSense in 2022 was to boost its mass spectrometry capabilities, a major application domain for glycan analysis. Similarly, GlycoNet's collaboration with BridgeBio Pharma in 2021 was to develop drugs for genetic diseases based on glycobiology research. 'Thermo Fisher Scientific (US)', 'New England Biolabs (US)', 'Merck KGaA (Germany)', 'Promega Corporation (US)', 'Waters Corporation (US)', 'Takara Bio Inc, (Japan)', 'Bio-Techne (US)', 'Agilent Technologies (US)', 'Sumitomo Bakelite Co. Ltd. (Japan)', 'Bruker Corporation (US)', 'Shimadzu Corporation (Japan)', 'Danaher Corporation (US)', 'AMS Bio (UK)', 'Ludger Ltd (UK)', 'Z Biotech, LLC (US)', 'Chemily Glycoscience (US)', 'CD BioGlyco (US)', 'GlycoDiag (France)', 'Kode Biotech Limited (New Zealand)', 'Glyxera GmBH (Germany)'

Governments across the globe are spending a lot on glycomics research to enhance health. The government of Australia, for instance, used over USD 10 billion in scientific research innovation between 2017 and 2018, while Ireland used USD 5.6 billion in 2015 on enhancing research activities, with the aim of growing scientific research personnel from 25,000 to 40,000. The investments are driving the growth of the glycobiology market through enhancement and enhanced research capacity. ​

​ North America is the world number one market for the glycobiology industry and is expected to have a market share of approximately 46.3% by the year 2025. This is because of the massive investments by public and private institutions in research and development. Federal governments, especially the U.S. National Institutes of Health (NIH), have significantly invested in research on glycomics to develop numerous groundbreaking solutions. Collaborations between academia and industry have also strengthened the research environment further, leaving North America at a commanding position as far as clinical applications of glycomics technologies are concerned.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Feedback From Our Clients

Global Glycobiology Market
Glycobiology Market

Report ID: SQMIG35H2335

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE